BridgeBio Pharma (BBIO) Short-term Investments (2019 - 2026)

BridgeBio Pharma has disclosed Short-term Investments across 8 years of filings, most recently posting $60.3 million for Q1 2026.

• Short-term Investments for Q1 2026 came in at $60.3 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $60.3 million (changed N/A YoY), and the FY2025 annual result was $17.4 million, changed N/A from the prior year.
• Short-term Investments came in at $60.3 million for Q1 2026 at BridgeBio Pharma, up from $17.4 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $261.9 million in Q1 2022 to a low of $3.0 million in Q3 2025.
• The 5-year median for Short-term Investments is $48.4 million (2022), against an average of $77.1 million.
• Across the five-year window, Short-term Investments surged 21329.38% in 2022 and sank 94.31% in 2025, its largest moves.
• BridgeBio Pharma's Short-term Investments stood at $37.9 million in 2022, then jumped by 55.42% to $58.9 million in 2023, then jumped by 136.49% to $139.4 million in 2024, then tumbled by 87.55% to $17.4 million in 2025, then soared by 247.26% to $60.3 million in 2026.
• The last three Short-term Investments figures came in at $60.3 million (Q1 2026), $17.4 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.